IP Library Granted Patent US 9,006,486
Granted Patent B2
US 9,006,486 · App. 14/149,027 · Granted Apr 14, 2015

Synthesis of N

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,006,486
App. No.
14/149,027
Granted
Apr 14, 2015
Kind
B2
Abstract

The present disclosure generally relates to a new process for the preparation of high purity 5-nitro-isophthalamide compounds, which are useful as intermediates for the preparation of imaging agents, such as iodinated x-ray contrast imaging agents like ioversol, iohexyl and iopamidol.

Claims (37)

1. A process for preparing a diamide compound of formula (2), the process comprising:

(i) forming a reaction mixture comprising a diester of formula (1),

a primary amine of formula RNH.sub. 2 , a basic catalyst and a solvent; and

(ii) heating the reaction mixture to a reaction temperature of from about 25° C. to less than 65° C. and holding the reaction mixture at the reaction temperature for a reaction time sufficient to generate a reaction product mixture comprising diamide compound formula (2)

wherein,

R, R 1 and R 2 independently selected from C 1 to C 18 straight or branched chain hydrocarbyl or substituted hydrocarbyl, and

the molar ratio of the primary amine to the diester is from 2:1 to about 2.4:1;

wherein the reaction product mixture comprises the diamide of formula (2) and at least one of the diester of formula (1), an acid amide of formula (3), an amide ester of formula (4) or an amide ester of formula (5)

wherein the wherein the content of the acid amide of formula (3) is about 2% or or less, by weight of the sum of the content of formulae (1) through (5).

2. R is selected from 2-hydroxyethyl, 2,3-dihydroxypropyl, 3-hydroxypropyl, 3,4-dihydroxybutyl, 4-hydroxybutyl and 1,3-dihydroxy isopropyl.

3. The process of claim 1 , wherein R 1 and R 2 are independently selected from methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl and t-butyl.

4. The process of claim 1 , wherein the solvent comprises methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, 2-methoxymethanol, 2-ethoxyethanol, 3-methoxypropanol, formamide, N-methylformamide, or combinations thereof.

5. The process of claim 1 , wherein the basic catalyst is a salt of an alkali metal and an alkoxide or an alkaline earth metal and an alkoxide.

6. The process of claim 5 , wherein the metal is selected from sodium, potassium, lithium and magnesium, and the alkoxide is selected from methoxide, ethoxide, i-propoxide, t-butoxide and amoxide.

7. The process of claim 1 , wherein the molar ratio of the primary amine to the diester is from 2:1 to about 2.4:1, from about 2.1:1 to about 2.2:1, from about 2.1:1 to about 2.3:1, or between about 2:1 and about 2.1:1.

8. The process of claim 1 , wherein the molar ratio of the catalyst, on an equivalent basis, to the diester is from about 0.03:1 to about 0.1:1, from about 0.04:1 to about 0.1:1, from about 0.05:1 to about 0.09:1, or from about 0.06:1 to about 0.08:1.

9. The process of claim 1 , wherein the concentration of the diester of formula (1) in the reaction mixture is from about 1 to about 10 moles per liter, from about 2 to about 10 moles per liter, from about 3 to about 10 moles per liter, from about 4 to about 10 moles per liter, or from about 4 to about 8 moles per liter.

10. The process of claim 1 , wherein the reaction temperature is from about 25° C. to about 60° C., from about 25° C. to about 50° C., from about 25° to about 40° C., from about 25° C. to about 35° C., or from about 30° C. to about 40° C.

11. The process of claim 1 , wherein the reaction time is from about 1 hour to about 12 hours, from about 1 hour to about 8 hours, from about 1 hour to about 6 hours, from about 1 hour to about 4 hours, from about 1 hour to about 3 hours, from about 1 hour to about 2 hours, from about 2 hours to about 6 hours, or from about 2 hours to about 4 hours.

12. The process of claim 1 , wherein the content of the diamide of formula (2) is about 95%, about 96%, about 97%, about 98%, about 99% or more by weight of the sum of the content of formulae (1) through (5), as measured by high pressure liquid chromatography.

13. The process of claim 1 , wherein the content of the diester of formula (1) is about 1%, about 0.5%, about 0.3%, about 0.1%, about 0.05%, about 0.03%, about 0.01%, or less by weight of the sum of the content of formulae (1) through (5), or is non-detectable by high pressure liquid chromatography.

14. The process of claim 1 , wherein the content of the amide ester of formulae (4) and (5) is about 0.5%, about 0.3%, about 0.1%, about 0.08% about 0.06%, about 0.04%, about 0.02%, about 0.01% or less by weight of the sum of the content of formulae (1) through (5), or is non-detectable by high pressure liquid chromatography.

15. The process of claim 1 , wherein:

R is 2,3-dihydroxypropyl;

R 1 and R 2 are —-CH 3 ;

the catalyst is sodium methoxide;

the solvent comprises methanol;

the molar ratio of the primary amine to the diester is from about 2.04 to about 2.08;

the molar ratio of the catalyst, on an equivalent basis, to the diamide is from about 0.05:1 to about 0.09:1;

the reaction temperature is from about 25° C. to about 40° C.; and

the reaction time is from about 1 hour to about 3 hours.

16. The process of claim 15 , wherein the content of the diamide of formula (2) is at least about 96% by weight, the content of the diester of formula (1) is less than about 0.1% by weight, the content of the acid amide of formula (3) is less than about 2% by weight, and the content of the amide ester of formulae (4) and (5) is less than about 0.1% by weight of the content of the sum of the content of formulae (1) through (5).

17. The process of claim 1 , further comprising

isolating the diamide compound of formula (2);

purifying the isolated diamide compound; and

reducing the purified diamide compound by hydrogenation to form a 5-amino isophthalamide of formula (6):

18. The process of claim 17 , wherein the purification is carried out by ion exchange chromatography.

Assignments (5)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTEREST Recorded Nov 30, 2015
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: LIEBEL-FLARSHEIM COMPANY LLC
Reel/Frame 037172/0094 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2014
From: MALLINCKRODT LLC
To: LIEBEL-FLARSHEIM COMPANY LLC
Reel/Frame 034715/0531 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2014
From: MEYER, JAMES R.
To: MALLINCKRODT LLC
Reel/Frame 031905/0039 →